# US 2021/0277061 A1 · Yeats inhibitors and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277061 A1
- Document ID: US20210277061A1
- Status: Published application
- Kind: A1
- Application number: 16/767,434
- Filed: 2018-11-26
- Published: 2021-09-09
- Earliest claimed: 2017-11-27
- Assignees: The University of Hong Kong
- Applicants: The University of Hong Kong
- Inventors: Xiang David Li; Xin Li
- Web page: https://patentgrep.com/patent/US20210277061A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 7/50: Cyclic peptides containing at least one abnormal peptide link
- C07K 14/001: {by chemical synthesis}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are compositions and methods suitable for treating acute leukemia by inhibiting π π π stacking in the YEATS protein domain. YEATS protein domains are typically found in a variety of chromatin modification molecular complexes. Cancer cells are characterized by aberrant epigenetic landscapes and often exploit chromatin machinery to activate oncogenic gene expression programs. Quantitative analysis of the inhibitory activity of YEATS domain inhibitors by use of a fluorescence-based assay revealed that several of the tested inhibitors achieved 50% inhibition at the submicro/nanomolar level. As such, provided is the use of small molecule inhibitors that target the ENL YEATS domain to selectively kill leukemic MLL-r cells.

## Claims

### Claim 1

A compound or a pharmaceutically acceptable salt thereof comprising a base oligomer and a side chain,
wherein the compound is defined according to Formula (I):
wherein A is CR2 or N;
wherein each instance of B1 and B2 is an independently selected bivalent linking unit, wherein the bivalent linking units are connected by amide, ester, thioester, thioamide, imidate, imide, sulfonate, or sulfonamide linkage in a head-to-tail manner;
wherein D1 is H or unsubstituted or substituted hydrocarbyl, carbocyclyl or heterocyclyl;
wherein D2 is H, NH2, NHR15, NR16R17, OH, OR18, or unsubstituted or substituted hydrocarbyl, carbocyclyl or heterocyclyl;
wherein X is unsubstituted or substituted C1-10 alkyl, C1-10 alkenyl, C1-10 alkynyl, C1-10 carbocyclyl, C1-10 heteroalkyl, C1-10 heteroalkenyl, C1-10 heteroalkynyl, or C1-10 heterocyclyl;
wherein Y is NR3, O, or S;
wherein Z is —CO—, —CS—, —CNR4—, —SO—, or —SO2—;
wherein R2, R3, and R4 are independently H or C1-10 hydrocarbyl, C1-10 carbocyclyl, or C1-10 heterocyclyl;
wherein R1 is a conjugated/delocalized group, such as an unsubstituted or substituted, heterocyclic or carbocyclic, aromatic ring (monocyclic, bicyclic, tricyclic, tetracyclic) or unsubstituted or substituted alkenyl or alkynyl;
wherein R15, R16, R17, and R18 can be H or alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C3-C20 cyclic, substituted C3-C20 cyclic, heterocyclic, or substituted heterocyclic; and
wherein m and n are each independently integers from 0 to 10, wherein at least one of m or n is not 0.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is defined according to Formula (II):
wherein each instance of J1 and J2 is independently any α-amino acid;
wherein R1 is a conjugated/delocalized group, such as an unsubstituted or substituted, heterocyclic or carbocyclic, aromatic ring (monocyclic, bicyclic, tricyclic, tetracyclic) or unsubstituted or substituted alkenyl or alkynyl; and
wherein m and n are each independently integers from 0 to 10, wherein at least one of m or n is not 0.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound is defined according to Formula (III):
wherein each instance of J1 and J2 is independently any α-amino acid;
wherein X is an unsubstituted or substituted C1-10 alkyl, C1-10 alkenyl, C1-10 alkynyl, C1-10 carbocyclyl, C1-10 heteroalkyl, C1-10 heteroalkenyl, C1-10 heteroalkynyl, or C1-10 heterocyclyl;
wherein Y is NR3, O, or S;
wherein Z is —CO—, —CS—, —CNR4—, —SO—, and —SO2—;
wherein R3 and R4 are independently H or C1-10 hydrocarbyl, C1-10 carbocyclyl or C1-10 heterocyclyl;
wherein R1 is a conjugated/delocalized group, such as an unsubstituted or substituted, heterocyclic or carbocyclic, aromatic ring (monocyclic, bicyclic, tricyclic, tetracyclic) or unsubstituted or substituted alkenyl or alkynyl; and
wherein m and n are each independently integers from 0 to 10, wherein at least one of m or n is not 0.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is defined according to Formula (IV):
wherein each instance of E1 and E2 is independently an unsubstituted or substituted C1-10 alkyl, C1-10 alkenyl, C1-10 alkynyl, C1-10 carbocyclyl, C1-10 heteroalkyl, C1-10 heteroalkenyl, C1-10 heteroalkynyl, or C1-10 heterocyclyl, or O, S, or NR5;
wherein X is an unsubstituted or substituted C1-10 alkyl, C1-10 alkenyl, C1-10 alkynyl, C1-10 carbocyclyl, C1-10 heteroalkyl, C1-10 heteroalkenyl, C1-10 heteroalkynyl, or C1-10 heterocyclyl;
wherein Y is NR3, O, or S;
wherein Z is —CO—, —CS—, —CNR4—, —SO—, or —SO2—;
wherein R3, R4, and R5 are independently a H, C1-10 hydrocarbyl, C1-10 carbocyclyl or C1-10 heterocyclyl;
wherein R1 is a conjugated/delocalized group, such as an unsubstituted or substituted, heterocyclic or carbocyclic, aromatic ring (monocyclic, bicyclic, tricyclic, tetracyclic) or unsubstituted or substituted alkenyl or alkynyl; and
wherein m and n are each independently integers from 0 to 10, wherein at least one of m or n is not 0.

### Claim 5 (depends on 1)

The compound of claim 1, wherein at least two of the instances of B1 linking units comprise side chains, wherein two of the side chains of the B1 linking units are covalently coupled to each other forming a circular oligomer.

### Claim 6 (depends on 5)

The compound of claim 5, wherein the compound is defined according to Formula (V):
wherein R1 is a conjugated/delocalized group, comprising unsubstituted or substituted aromatic rings (monocyclic, bicyclic, tricyclic, tetracyclic), unsubstituted or substituted alkenyl or alkynyl;
wherein R6, R7, R8, R9, and R10 are independently H or C1-10 hydrocarbyl, C1-10 carbocyclyl or C1-10 heterocyclyl;
wherein each of G1, G2, and G3 is an unsubstituted or substituted C1-10 alkyl, C1-10 alkenyl, C1-10 alkynyl, C1-10 carbocyclyl, C1-10 heteroalkyl, C1-10 heteroalkenyl, C1-10 heteroalkynyl, or C1-10 heterocyclyl, or 5 to 9-membered heteroaryl; and
wherein i1, i2, j1, j2, k1, k2 are each independently integers from 0 to 10.

### Claim 7 (depends on 1)

The compound of claim 1, wherein at least two of the instances of B2 linking units comprise side chains, wherein two of the side chains of the B2 linking units are covalently coupled to each other forming a circular oligomer.

### Claim 8 (depends on 1)

The compound of claim 1, wherein the compound inhibits π-π-π stacking interactions.

### Claim 9 (depends on 1)

The compound of claim 1, wherein the compound selectively targets the YEATS protein domain.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising an effective amount of the compound of claim 1.

### Claim 11 (depends on 10)

The composition of claim 10, further comprising one or more pharmaceutically acceptable carriers or excipients.

### Claim 12 (depends on 10)

The composition of claim 10, wherein the compound selectively inhibits π-π-π stacking interactions.

### Claim 13 (depends on 10)

The composition of claim 10, wherein the compound selectively targets the YEATS protein domain.

### Claim 14 (depends on 10)

The composition of claim 10, wherein the compound is effective for treating cancer.

### Claim 15 (depends on 10)

The composition of claim 10, wherein the cancer is acute leukemia.

### Claim 16 (depends on 10)

A method for treating cancer, the method comprising administering the composition of claim 10 to a subject in need thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the subject has acute leukemia.
